John P. Feighner
Corporate Officer/Principal bij University of California San Diego
Actieve functies van John P. Feighner
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| University of California San Diego | Corporate Officer/Principal | 05-02-2010 | - |
| Hoofd Techniek/Wetenschap/O&O | 05-02-2010 | 09-02-2010 |
Loopbaan van John P. Feighner
Eerdere bekende functies van John P. Feighner
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Tetragenex Pharmaceuticals, Inc.
 Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | Directeur/Bestuurslid | 01-10-1999 | 02-01-2006 |
| Charter Hospital of Indianapolis | Hoofd Techniek/Wetenschap/O&O | 02-01-1995 | 02-01-1995 |
| Institute for Creation Research | Hoofd Techniek/Wetenschap/O&O | 02-01-1992 | 02-01-1992 |
| Oprichter | 02-01-1992 | 02-01-1992 | |
| Corporate Officer/Principal | 02-01-1992 | 02-01-1992 | |
| San Luis Rey Equine Hospital | Hoofd Techniek/Wetenschap/O&O | 02-01-1988 | 02-01-1988 |
| Feighner Research Institute | Oprichter | - | - |
| President | - | - |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Chief Tech/Sci/R&D Officer | 4 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Sectoraal
| Health Technology | 2 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | Health Technology |
| Institute for Creation Research | |
| Feighner Research Institute | |
| San Luis Rey Equine Hospital | |
| Charter Hospital of Indianapolis |
- Beurs
- Insiders
- John P. Feighner
- Ervaring
